MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2025 International Congress
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • 2025 International Congress

    Effects of Allogeneic Bone Marrow-Derived Mesenchymal Stem Cell Therapy on Motor Complications in Parkinson’s Disease

    E. Tharp, J. Martinez-Lemus, C. Onuigbo, T. Thomas, C. Green, J. Suescun, T. Le, E. Rodarte, R. Ritter Iii, T. Ellmore, M. Schiess (New York, USA)

    Objective: To evaluate the impact of intravenous (IV) allogeneic bone marrow-derived mesenchymal stem cell (allo-hMSC) treatment on motor complications in Parkinson’s disease (PD). Background: Motor…
  • 2025 International Congress

    Lived Experiences in early clinical PD: Developing a Framework of a Novel Patient-reported Outcome (PRO) Fit-for-purpose for Disease Modification Therapeutic Trials

    T. Mestre, J. Ding, N. Lapelle, G. Stebbins (Chicago, USA)

    Objective: To characterize the lived experience of individuals at a prodromal stage of PD or with a recent clinical diagnosis. Background: There is no validated…
  • 2025 International Congress

    Findings of motoric and neuro psychological outcome using high frequency stimulations in Parkinsons with STN-DBS

    A. Dabbeta, V. Rama Raju (Hyderabad, India)

    Objective: For testing the likelihood of decreasing psychiatric dyskinesias of STN-DBS, conducting experimentally and through experimental studies we explore the properties of in what best…
  • 2025 International Congress

    The effect of trial numbers on prism adaptation in Parkinson’s disease

    K. Taneda, T. Shimizu, N. Tokuda, S. Moriyasu, T. Nakamura, T. Murakami, Y. Ugawa, R. Hanajima (Yonago, Japan)

    Objective: We aimed to investigate the relationship between exposure trials and the acquisition of prism adaptation or the after-effect (AE) in patients with Parkinson's disease…
  • 2025 International Congress

    Investigating the Neuroprotective Potential of Mushroom Extracts in Parkinson’s Disease In Vitro Models

    SEO. Seo, FAZ. Dustov (Tashkent, Uzbekistan)

    Objective: This study aims to evaluate the neuroprotective potential of various mushroom extracts in in vitro models of PD. Background: Parkinson’s disease (PD) is a…
  • 2025 International Congress

    Cognitive Effects of Istradefylline in Parkinson’s Disease: A 26-Week Open-Label Pilot Study

    M. Barrett, R. Heo, N. Mukhopadhyay (Richmond, USA)

    Objective: The objective of this study was to collect preliminary evidence whether istradefylline may improve cognition in Parkinson’s disease (PD) patients with cognitive impairment. Background:…
  • 2025 International Congress

    Effect of Antihypertensive Agent Choice on Parkinson’s Disease Progression in Patients with Hypertension

    R. Gologorsky, A. Zolin, H. Ooi, H. Sarva (New York, USA)

    Objective: To determine the effect of different classes of antihypertensive medications on Parkinson’s disease progression. Background: Cardiovascular risk factors such as hypertension can worsen Parkinson’s…
  • 2025 International Congress

    Apomorphine Sublingual Film’s Efficacy in Elderly Patients with Parkinson’s Disease: Post-hoc Analysis of Study CTH-301

    F. Moreira, L. Wojtecki, W. Jost, D. Santos Garcia, J. Kassubek, M. Fonseca, H. Brigas, G. Harrison-Jones, I. Pijuan (Duesseldorf, Germany)

    Objective: This study evaluated the efficacy of apomorphine sublingual film (SL-APO) in elderly (≥70 years) and younger (<70 years) patients over the long term. Background:…
  • 2025 International Congress

    Treatment with Mucuna pruriens Plus Solo Carbidopa Prescription in Patient Reluctant to Initiation of Traditional Levodopa/Carbidopa Medication

    T. Denne (Mission Viejo, USA)

    Objective: To see if treatment with Mucuna pruriens 2 capsules (15% levodopa) TID, plus solo carbidopa prescription 25mg TID in patient reluctant to traditional levodopa/carbidopa management could help…
  • 2025 International Congress

    Medication therapy in Parkinson’s disease patients: a cross-sectional study at the University Medical Center at Ho Chi Minh City, Vietnam

    T. Dang, T. Tran (HO CHI MINH, Viet Nam)

    Objective: To determine the rate of drugs prescribed to treat Parkinson's disease motor symptoms, the rate of the types of drug combinations, and the frequency…
  • « Previous Page
  • 1
  • …
  • 158
  • 159
  • 160
  • 161
  • 162
  • …
  • 181
  • Next Page »

Most Viewed Abstracts

  • This Month
  • All Time
  • Welcome to the MDS Abstracts Site
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • #24970 (not found)
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
    • Help & Support
    • About Us
    • Cookies & Privacy
    • Wiley Job Network
    • Terms & Conditions
    • Advertisers & Agents
    Copyright © 2026 International Parkinson and Movement Disorder Society. All Rights Reserved.
    Wiley